Specialty Drug Sales Give Teva Pharmaceutical Industries Ltd. a Boost in Q2

By Keith SpeightsMarketsFool.com

Image source: Getty Images.

Continue Reading Below

It hasn't been the greatest year so far for Teva Pharmaceutical Industries (NYSE: TEVA) shareholders. The drugmaker's stock is down over 18% year to dateand has been stuck at that level or lower for the past three months.

Teva announced its second-quarter results before the market opened on Thursday. Were those results good enough to light a fire under the stock? Here are the highlights.

Teva results: The raw numbers

More From Fool.com

YOY = Year over year. Data source: Teva.

What happened with Teva this quarter

Teva's revenue continued to be negatively impacted by currency headwinds in the second quarter. The company noted that revenue for the quarter would have been up 4% year over year excluding the impact of currency fluctuations.

Non-GAAP earnings for the second quarter were $1.23 billion, essentially flat compared to the prior-year period. Teva reported second-quarter non-GAAP earnings of$1.25 per diluted share, down from the $1.45 per diluted share posted in the same quarter last year because of issuance of more shares since then. However, the company's non-GAAP earnings topped investors' expectations.

Generic revenue fell 33% year over year. Loss of exclusivity for generic versions of Abilify, Nexium, and Pulmicort had the biggest impact on revenue from generics. Lower sales for these drugs also largely accounted for an 11% decline in gross profit for Teva's generic medicines business.

The good news came from specialty pharmaceuticals. Teva reported specialty drugs revenue increased 9% year over year, to $2.3 billion. The biggest moneymaker continued to be Copaxone, which saw sales climb 8% from the prior-year period, to $1.14 billion, thanks in part to lower Medicaid rebates. Teva's rising star, though, is QVAR. Sales for the respiratory drug jumped 40% year over year.

What management had to say

Erez Vigodman, Teva's president and CEO, focused primarily on his company's position for the future. Vigodman stated:

Looking forward

Teva projects that revenue for 2016 should be between $22 billion and $22.5 billion. The company expects full-year non-GAAP earnings per share between $5.20 and $5.40. Both ranges are in line with what Wall Street expects for 2016.

Much of Teva's future success hinges on how well it integrates the businesses that it has acquired -- and will soon acquire -- from Allergan (NYSE: AGN). Teva closed its deal to buy Allergan's generics business unit on Aug. 2. The next day, the Israel-based drugmaker announced plans to also buy Allergan's Anda, Inc., the fourth-largest distributor of generic drugs in the U.S.

The first deal with Allergan came at a price tag of over $40 billion. That makes the cost of Anda seem small by comparison at only $500 million. Teva expects to gain around $1.4 billion annually from cost synergies. The company also anticipates non-GAAP earnings-per-share gains of 14% in 2017 and 19% in 2018.

Integration of the Allergan business could transform Teva. Investors will want to watch for any hiccups with assimilation of the new units. Its important to keep an eye also on how effectively Teva manages the debt it took on to fund the Allergan generics purchase. If the company accomplishes what it says it will, though, these recent acquisitions should bode well for Teva's future.

A secret billion-dollar stock opportunity The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.

Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.